C4 Therapeutics, Inc.
CCCC Healthcare Biotechnology
C4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024. In the quarter to June 2026, revenue grew 2.75%, EPS grew 51.4% and free cash flow grew 86.8%, each against the same quarter a year earlier.
Follow CCCC
C4 Therapeutics, Inc. (CCCC) EV/Sales
As of 16 October 2026, C4 Therapeutics, Inc. (CCCC) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −10.0× (September 2023) to 55.4× (November 2021); the current reading is higher than 56% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −2.0× | — |
| FY2024 | 0.7× | (84.39%) |
| FY2023 | 4.3× | 183.09% |
| FY2022 | 1.5× | (94.15%) |
| FY2021 | 25.9× | 5,240.35% |
| FY2020 | 0.5× | — |
| FY2019 | −4.9× | — |
| FY2018 | −4.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.7× | 225.39% |
| Mar 2026 | 3.3× | — |
| Dec 2025 | −2.0× | — |
| Sep 2025 | −0.4× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | 0.4× |
| ENTA Enanta Pharmaceuticals, Inc. compare | 2.0× |
| CCCC C4 Therapeutics, Inc. | 3.6× |
| FENC Adherex Technologies Inc. compare | 5.4× |
| OBIO Orchestra BioMed Holdings, Inc. compare | 8.5× |
| IRD Opus Genetics, Inc. compare | 31.5× |
| CYPH Cypherpunk Technologies Inc. compare | 311× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)